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Early-onset major depressive disorder (MDD) is a serious and prevalent psychiatric illness in adolescents and young adults.
Current treatments are not optimally effective. Biological markers of early-onset MDD could increase diagnostic speciﬁcity, but
no such biomarker exists. Our innovative approach to biomarker discovery for early-onset MDD combined results from genome-
wide transcriptomic proﬁles in the blood of two animal models of depression, representing the genetic and the environmental,
stress-related, etiology of MDD. We carried out unbiased analyses of this combined set of 26 candidate blood transcriptomic
markers in a sample of 15–19-year-old subjects with MDD (N¼14) and subjects with no disorder (ND, N¼14). A panel of 11
blood markers differentiated participants with early-onset MDD from the ND group. Additionally, a separate but partially
overlapping panel of 18 transcripts distinguished subjects with MDD with or without comorbid anxiety. Four transcripts,
discovered from the chronic stress animal model, correlated with maltreatment scores in youths. These pilot data suggest that
our approach can lead to clinically valid diagnostic panels of blood transcripts for early-onset MDD, which could reduce
diagnostic heterogeneity in this population and has the potential to advance individualized treatment strategies.
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Introduction
Early-onset major depressive disorder (MDD) is a serious
psychiatric condition occurring in people under 25 years of
age.
1 Early onset of MDD predicts greater familial risk,
suggesting a substantial genetic etiology.
2,3 Approximately
1% of the population of o12 years has MDD, but rates
increase to 17–25% by late adolescence and young adult-
hood.
4,5 Early-onset MDD carries a poorer prognosis than
adult onset, characterized by derailment of normal develop-
ment and, subsequently, increases in the prevalence of
substance use, physical illness, social maladjustment and
suicidality.
6–11 This dysfunction persists into adulthood with
continued mood disturbance, and often presents comorbid
anxiety and substance use disorders.
9,12
Treatments for early-onset MDD exist, but medication side
effects are unpredictable and adolescents have lower
response rates than adults.
13,14 Unmeasured heterogeneity
in the etiology of MDD and the presence of symptom cluster
subtypes that require unique treatments may explain these
problems.
15,16 Current diagnostic practice is limited to patient
self-report and clinician observation, methods that cannot
adequately characterize this heterogeneity. Biological mar-
kers of different etiologic pathways and/or endophenotypes
would provide objective data to augment verbal information
and improve the accuracy of diagnosis. The diagnosis
and classiﬁcation of early-onset MDD could lead to a larger
repertoire of more effective treatments and enhanced
individualized care.
The beneﬁt of having valid, reliable, selective and feasible
biomarkers for MDD is clear, but despite 30years of research,
we still do not have them.
17 Two approaches have been used
to search for blood biomarkers. The ﬁrst approach screens
candidate markers suggested by current knowledge of MDD
etiology, such as serum levels of cortisol
18 or brain-derived
neurotrophic factor.
19 The other approach takes an explora-
tory route through the use of omic technologies such as the
proteomic proﬁling for bipolar disorder
20 and transcriptomic
proﬁling for psychosis
21 or for mood disorders.
22 Each
approach has its advantages and challenges, but neither
has been successful in identifying biomarkers that survive
the tests of replication and selectivity.
23 In the present paper,
we describe a promising novel approach to discover blood
biomarkers, and a pilot study focusing on their validity for
distinguishing early-onset MDD from no disorder in youth.
Substantial evidence has accumulated for both the genetic
and the environmental stress-related etiologies of MDD.
Therefore, in our study we use a theoretical approach that
recapitulates these etiologies by utilizing animal models of
both. In previous studies, we have shown that the mole-
cular mechanisms through which genetic predisposition and
chronic stress precipitate depressive behavior are different.
24
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www.nature.com/tpAdditionally, these molecular pathways can interact, which
could hasten the onset of depression or increase the severity.
Therefore, if these models are explored in conjunction with
one another, a greater part of the spectrum of human MDD, or
its endophenotypes, can be accounted for.
The genetic model of depression is based on selective
breeding from the Wistar Kyoto (WKY) rat strain, with many
behavioral and physiological characteristics mirroring symp-
toms of patients with MDD.
25–29 The WKY strain is also
regarded as the optimal model for juvenile depression,
presumably because it is a genetic model and early-onset
MDD is associated with a greater familial risk.
2,30 The two
substrains of the WKY, identiﬁed as WKY More Immobile
(WMI, the depression model) and WKY Less Immobile (WLI,
the nondepressed control strain), were generated by bidirec-
tional selective breeding from the WKY strain based on
depressive behavior in the forced swim test.
24,31 These two
inbred strains have maintained clear and signiﬁcant behavior-
al differences in measures of depressive behavior over 25
generations; thus, the WMI strain represents a model of
genetic, or endogenous, depression. Furthermore, the WMI
rats show depressive-like behavior during early adoles-
cence.
32 The chronic stress model employed young adult
males of four phylogenetically, physiologically and behavio-
rally different strains of rats as described previously, and
half of the animals from each strain were exposed to
chronic restraint stress and the other half were not.
24 Genetic
polymorphisms between the strains ranged from 25.9 to 66%,
representing a substantial interstrain variation that aims at
mimicking individual variation among human subjects.
By conducting genome-wide expression analyses in the
bloodofbothofthesemodelsandtheirrespectivecontrols,we
arrived at a set of candidate transcripts whose abundance
we measured in the blood of human subjects. We elected to
monitortranscriptlevels,ratherthanserumproteinlevels,asa
more all-encompassing approach, as not all proteins are
secreted and not all transcripts are translated. More-
over, current technology allows the collection of blood for
RNA isolation without refrigeration, an additional practical
advantage.
The overarching goal of our research is to develop a panel
of blood biomarkers for early-onset MDD that are valid,
reliable and feasible. The core hypothesis for this study
was that the combined list of transcripts that differen-
tiated depressed-like from non-depressed-like rats would also
differentiatehumansubjectswithearly-onsetMDDfromthose
without any disorder. We also explored whether a subset
of these transcripts differentiated youths solely with MDD
from those with comorbid anxiety, which is one of the best-
described endophenotypes.
Materials and methods
Study 1: animal models and procedures. All procedures
were approved by the institutional animal care and use
committee of Northwestern University. The animals, dissec-
tion, RNA isolation, labeling, ampliﬁcation, hybridization and
scanning to identify ‘depression’ markers using the WMI and
WLI strains were described previously
24 with the following
modiﬁcations. Whole blood was also collected into PAXgene
Blood RNA tubes (PreAnalytiX, Hombrechticon, Switzerland)
from three males, derived from different litters, of each strain.
Brieﬂy, total RNA isolated from these four tissue sources was
reverse-transcribed with an Oligo(dT)-T7 primer (Affymetrix,
Santa Clara, CA, USA), and double-stranded complementary
DNA (cDNA) was synthesized with the GeneChip Expression
30-Ampliﬁcation One-cycle kit (Affymetrix). In an in vitro
transcription reaction with T7 RNA polymerase, the cDNA
was linearly ampliﬁed and labeled with biotinylated nucleo-
tides (Affymetrix).Atotalof10mg of biotin-labeled and fragmented
cRNA was then hybridized onto Rat Genome 230 2.0
GeneChip arrays (Affymetrix) for 16h at 451C. Post-hybri-
dization staining and washing were performed according to
the manufacturer’s protocols using the Fluidics Station 450
instrument (Affymetrix). Finally, the arrays were scanned with
a GeneChip Scanner 3000 laser confocal slide scanner.
For the determination of peripheral chronic stress markers,
whole blood was collected into PAXgene Blood RNA tubes
fromnonstressedandchronicallystressedFisher-344(F344),
Brown Norway (BN-SS), Lewis (Lew) and WKY male rats of
B100 days of age and of different litters (n¼3 per strain per
experimental condition). The chronically stressed animals
were restrained in a breathable decapicone for 2h per day for
a 2-week period. Total RNA was isolated using the PAXgene
Blood RNA Kit (Qiagen) according to the manufacturer’s
instruction, and then reverse transcribed followed by second-
strand cDNA synthesis. For each sample, an in vitro trans-
cription reaction was carried out incorporating biotinylated
nucleotides according to the manufacturer’s protocol for
Illumina Totalprep RNA ampliﬁcation kit (Ambion, Austin,
TX, USA). Then, 1.5mg biotin-labeled cRNA was hybridized
onto RatRef-12 Expression BeadChips (Illumina, San Diego
CA, USA) for 16h at 551C. Post-hybridization staining and
washing were performed according to the manufacturer’s
protocols (Illumina). Illumina Sentrix RatRef-12 v1.0 Bead-
Chips were scanned using Illumina’s BeadStation 500
scanner. Images were checked for grid alignment and then
quantiﬁed using the BeadStudio software.
The two sets of blood gene expression data came from
different microarray platforms. For this reason, we carried out
a detailed comparison between the Affymetrix and Illumina
platforms used, and validated a number of selected tran-
scripts’ abundances by quantitative real-time PCR (qPCR) as
described previously.
24
Statistical analyses of microarray data. Analyses to establish
signiﬁcant differences in gene expression between WMI and
WLI for the different tissues were carried out as described
previously.
24 Brieﬂy, probe intensity data from Rat 230v2
Affymetrix GeneChip arrays were read into the R software
environment (http://www.R-project.org) directly from .CEL
ﬁles using the R/affy package.
33 The normalization of the
Affymetrix data was performed by tissue type using the
robust multiarray average method for probe set data.
34
Probe intensity data from Illumina Chip arrays were read
into the R software environment directly from Bead summary
ﬁles produced by BeadStudio using the R/beadarray pack-
age.
35QuantilenormalizationwasappliedtotheIlluminabead
summary data using the R/preprocessCore package.
36 Data
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Translational Psychiatryquality was assessed using histograms of signal intensities,
scatterplots, and hierarchical clustering of samples.
Analysis of variance methods were used to statistically
resolve gene expression differences from both studies after
data processing and normalization using the R/maanova
package.
37,38
Study 2: human subjects: recruitment and procedures.
The study was carried out from May through September,
2009 and from July through December, 2010. Recruitment
and experimental protocols were exactly the same, except
for the addition in 2010 of a questionnaire about maltreat-
ment as a measure of chronic stress.
Male and female subjects, 15–19 years of age, were
recruited through community posters, other research studies
at the Research Institute at Nationwide Children’s Hospital,
the Nationwide Children’s Hospital (NCH) Adolescent Medi-
cine and Behavioral Health Clinics and private psychologists.
Exclusion criteria were: age outside 15–19 years; Tanner
Stage o5; major medical illness; antidepressant use in the
past 3 months; no MDD, but another psychiatric disorder;
MDD with psychosis; pregnancy; or history of mental retar-
dation. An additional exclusion criterion for the no disorder
(ND) group was any lifetime psychiatric disorder.
A total of 136 youths underwent telephone screening;
73 were not eligible or refused participation; 10 could not
be reached because of a disconnected phone. In total, 53
participants were scheduled for appointments.
Theprotocol wasapprovedbythe NCH InstitutionalReview
Board. Appointments took place at NCH Clinical Research
Services (CRS) with data collection standardized to 1600–
1700h. Consent and assent were obtained upon arrival to the
CRS. Blood was drawn into two PaxGene RNA (Qiagen)
tubes. Trained research assistants conducted concurrent, but
separate interviews with parents and youths about the young
person’s lifetime psychiatric symptoms and medical history.
A youth self-report questionnaire about exposure to maltreat-
ment was added in the 2010 subsample. Parents received
$30 for time and effort and transportation costs, and youths
received $45.
Pubertal stage was assessed with the Tanner Self-Rating
Schematic Drawings.
39 Demographic characteristics and the
youth’s lifetime medical history were evaluated through a brief
interview with the parent and the Risks and Disorders sub-
domains of the Child Health and Illness Proﬁle-Adolescent
Edition (CHIP-AE).
40 The lifetime history of psychiatric
diagnoses was assessed with the computerized version of
the Diagnostic Interview Schedule for Children and Adoles-
cents-IV (CDISC-IV; NIMH, 1998), Parent and Youth Ver-
sions. The CDISC is a structured psychiatric interview,
organized into six Axis I diagnostic sections: Anxiety
Disorders, Mood Disorders, Disruptive Behavior Disorders,
Schizophrenia, Miscellaneous Disorders (for example, Eating
Disorders) and Substance-Use Disorders.
41 Psychometric
testing of the CDISC has demonstrated good validity and
reliability.
42,43 Everyparticipant and parent receivedtheentire
diagnostic assessment.
In 2010, we also explored whether exposure to chronic
stress in humans, as deﬁned by maltreatment, correlated with
the levels of gene transcripts derived from the chronic stress
animal model. We used the Childhood Trauma Questionnaire
(CTQ), a 28-item self-report questionnaire measuring lifetime
exposure to ﬁve types of maltreatment: Emotional, Physical
and Sexual Abuse and Emotional and Physical Neglect. The
instrument has been standardized on over 2200 people,
including adolescents, and has excellent psychometric
properties.
44 We used the total CTQ score.
Determination of blood transcript levels of candidate
markers. Blood was drawn on all participants, but the only
samples sent to the Redei lab were those of youths suffering
from current MDD or those without any disorder (ND). The
Redei lab was blind to any information about the participants.
Whole-blood RNA was isolated using the PAXgene Blood
RNA Kit (Qiagen) according to the manufacturer’s instruction;
cDNA was prepared using random primers and the TaqMan
RT reagents (Applied Biosystems, Foster City, CA, USA).
Speciﬁc primers, listed in Supplementary Table S1, were
designed to amplify the human ortholog of the rat microarray
probe region of the candidate markers using the ABI’s Primer
Express Software (version 3.0, PE Applied Biosystems).
qPCR was carried out using SYBR Green and the ABI 7900
(Applied Biosystems), with 18s rRNA as the internal control.
18s was chosen as the normalizing gene after an extensive
comparative pilot study using several housekeeping genes
(data not shown). Each sample for each transcript was
measured in triplicate using 5ng of template.
The DCT values from qPCR were used to characterize
transcript abundance. DCT is the cycle threshold difference
betweenthetargetgeneandthehousekeepinggene,whichin
this case is 18s. This method, as opposed to the relative
quantiﬁcation approach in which the DCT values are normali-
zed to the control group giving DDCT, will also indicate the
variation within the ND samples. DDCT is the DCT of
the disorder group subtracting DCT of the ND group. The
relative expression for each transcript and each sample is
determined from DCT by raising 2 to the power of the negative
value of DCT. A fold change can then be calculated by raising
2 to the power of the negative value of DDCT for each sample.
Statistical analyses of human data. Descriptive statistics
were used to characterize the sample, and nonparametric
statistics to analyze gene expression differences between
the ND and MDD groups or between the MDD subgroups
with and without comorbid anxiety disorders. Spearman’s rho
correlation coefﬁcients were used to evaluate the relation-
ships between the CTQ scores and gene expression levels.
Because this is a pilot study, effect sizes are more infor-
mative than statistical signiﬁcance. We calculated effect
sizes for all differences between means, using Hedges’
because of small sample and unequal subgroup sizes.
Correlation coefﬁcients themselves can serve as estimates
of effect sizes, and hence we report rho values for these
analyses. We made an a priori decision to interpret an effect
size of X0.50 as clinically signiﬁcant, which corresponds to
Cohen’s medium effect size.
45 We did not control for multiple
comparisons, as the goal of a pilot study is to detect as many
potentially clinically signiﬁcant relationships as possible. Data
analyses were performed with SPSS 14.0 (SPSS Inc.,
Chicago, IL, USA).
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Identiﬁcation of candidate biomarker transcripts.
Candidate transcripts were selected with signiﬁcant
(Po0.01) expression differences between WMI and WLI
and an absolute fold change 41.2, or 20%. Using these
criteria, 238 differentially expressed and annotated
transcripts were identiﬁed in the hippocampus (Supple-
mentary Table S2). Of these, 60.5% had greater abun-
dance in the WLI hippocampus compared with the WMI.
Congruent selection criteria resulted in 396 annotated trans-
cripts from the amygdala (Supplementary Table S3), of which
141 (35.6%) had a greater abundance in WLI amygdala. The
analyses of blood microarray data were carried out similarly.
These differentially expressed blood transcripts and their
human orthologs are listed in Supplementary Table S4.
There were 203 transcripts differentially expressed between
WMI and WLI blood, and 167 transcripts (82.3%) had greater
abundance in WLI as it is clearly visualized in the volcano
plot (Figure 1a).
Overlap between differentially expressed transcripts in
either of the two brain regions and blood was established.
The 11 transcripts selected as candidates had to fulﬁll the
criteria that the directional changes had to agree between
brain and blood. Seven of these candidates (MARCKS, MAF,
FAM46A, NAGA, UBE3A, CD59, ATP11C and RAPH1)
fulﬁlled the selection criteria above and overlapped between
brain and blood. Additionally, we selected three genes,
SCAPER/ZNF291, TLR7 and IGSF4A/CADM1, whose tran-
scriptlevelsdifferedbetweenWMIandWLIbloodbythesame
criteria as the others, but were selected from brain regions
based on either high fold change (fold change 41.2) or high
signiﬁcance (Po0.01). These transcripts, therefore, could
have potential clinical relevance.
The selection criteria for the chronic stress markers differed
from those of the genetic model, as they are related to a
change induced by environment, rather than individual
variation to vulnerability. Chronic restraint stress affected all
strains of rats, as described previously.
24 To eliminate strain-
speciﬁc effects in our selection, transcripts were selected
based on consistent, signiﬁcant expression level differences
in all four strains, in which signiﬁcance was set at Po0.001
andabsolutefoldchangeat41.2.Wefound125transcriptsin
the blood that had differentially expressed transcript levels
between the chronic restraint stress and no stress conditions
(Figure 1b and Supplementary Table S5). From these, we
randomly selected 15 representative transcripts with absolute
fold change between 1.28 and 1.95.
During the selection processes we eliminated candidates if
they did not have human orthologs, or if the mRNA sequence
that the probes were designed for had been retired or
retracted in the database. Additionally, we also eliminated
candidatesthathadUniGeneEST(expressedsequencetag)-
only information, as we could not identify associated mRNAs.
Participant characteristics. Of the 53 participants
examined, 28 (14 MDD and 14 with ND) met all criteria for
inclusion in testing blood transcript levels of candidate
markers. There were no statistically signiﬁcant differences
between the two groups in mean age, proportion of females
or proportion of African-Americans and Caucasians. Table 1
displays the characteristics of our ﬁnal study group.
Transcript-level differences: MDD vs ND. Mean transcript
abundance levels for the MDD and ND groups are shown in
Table 2. The number of subjects (n) varies by one because
some of the qPCR analyses were repeatedly unsuccessful
for the particular subject and transcript, possibly because of
polymorphisms located in the primer sequence(s). Medium
or large effect sizes were found for group mean differences in
11 of the 26 transcripts examined (Table 3). The corres-
ponding genes are ATP11C, CD59, IGSF4/CADM1, MAF
and RAPH1 (derived from the genetic model); and AMFR,
CAT, CDR2, CMAS, PSME1 and PTP4A3 (derived from the
chronic stress model).
Transcript-level differences: MDD-only vs MDD with
anxiety disorders. Intragroup analyses of MDD with and
without comorbid anxiety disorders revealed medium to large
effect size differences in 18 of the 26 candidate biomarkers:
CD59, FAM46A, IGSF4A/CADM1, NAGA, TLR7 and
ZNF291/SCAPER as well as AHSP, AMFR, CAT, CDR2,
CMAS, DGKA, GCLM, GGA3, IRF3, KIAA1539, PSME1 and
SLC4A1 (Table 3). This panel diverged in three ways from
the panel that differentiated MDD from ND. First, the list of
potentially clinical markers was longer for the intra-MDD
analyses. Second, the two panels for MDD versus ND and
MDD with-versus-without anxiety disorders only overlapped
by six genes; thus, the non-overlapping candidates FAM46A,
NAGA, TLR7, ZNF291/SCAPER, AHSP DGKA, GCLM,
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Figure 1 Volcano plots based on microarray analyses depicting individual
probe P-value ( log10) versus expression fold change (log2). (a) WMI/WLI (Wistar
Kyoto (WKY) More Immobile (WMI) and WKY Less Immobile (WLI)) blood
microarray plot, with dotted lines depicting the P-value selection threshold
(Po0.01) and the fold change (FC) threshold (absolute FC 41.20). (b) Chronic
stress blood microarray plot, with dotted lines depicting the P-value selection
threshold (Po0.001) and the fold change threshold (absolute FC 41.20).
Table 1 Characteristics of human participants
Variable MDD (n¼14) ND (n¼14) P-value
Age (mean±s.d.) 16.6±1.3 years 16.2±1.5 years 0.51
Sex (% female) 9 (64%) 12 (86%) 0.39
Race (% Caucasian) 8 (57%) 10 (71%) 0.70
Abbreviations: MDD, major depressive disorder; ND, no disorder.
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Translational PsychiatryTable 2 Descriptive statistics of blood transcript abundance differences between subjects with no disorder (ND), major depressive disorder (MDD)-only or MDD with
comorbid anxiety disorder
Groups N Mean, DCt
a s.d. DDCt
b Fold change
c
Endogenous depression genes
ATP11C ND 14 14.9232 0.74081 0 1
MDD only 5 15.2596 0.23454 0.3364  1.26263
MDD + anxiety disorder 8 15.0147 0.55075 0.0915  1.06542
CD59 ND 14 13.9868 0.59346 0 1
MDD only 5 14.6551 0.09019 0.6683  1.58907
MDD + anxiety disorder 9 14.2498 0.49290 0.2630  1.20005
FAM46A ND 14 15.6206 0.62560 0 1
MDD only 5 15.3099 0.51630  0.3107 1.2403
MDD + anxiety disorder 9 15.7898 0.60560 0.1692  1.12448
CADM1/IGSF4A ND 14 16.5055 2.63519 0 1
MDD only 5 18.4211 0.68470 1.9156  3.77216
MDD + anxiety disorder 9 17.3174 1.23838 0.8119  1.75562
MAF ND 14 17.7071 0.88667 0 1
MDD only 5 18.1239 0.58738 0.4168  1.33494
MDD + anxiety disorder 9 18.1815 0.55424 0.4743  1.38927
MARKS ND 14 13.2903 1.42679 0 1
MDD only 5 13.5260 0.57322 0.2357  1.17744
MDD + anxiety disorder 9 13.9042 1.08966 0.6139  1.53046
NAGA ND 14 13.9092 0.83357 0 1
MDD only 5 13.6951 0.53240  0.2141 1.16
MDD + anxiety disorder 9 14.3758 0.73741 0.4666  1.38179
RAPH1 ND 14 15.7073 2.56428 0 1
MDD only 5 17.1122 0.82167 1.4049  2.64831
MDD + anxiety disorder 8 16.8285 1.18044 1.1211  2.17533
TLR7 ND 14 15.4338 0.85478 0 1
MDD only 5 15.0418 0.56444  0.3920 1.3122
MDD + anxiety disorder 9 15.6474 0.63404 0.2136  1.15955
UBE3A ND 14 15.1981 1.65462 0 1
MDD only 5 15.8918 0.32713 0.6937  1.61734
MDD + anxiety disorder 8 15.3906 1.41887 0.1925  1.14273
SCAPER/ZNF291 ND 14 16.1619 1.15379 0 1
MDD only 5 16.1685 0.59014 0.0066  1.00462
MDD + anxiety disorder 9 16.6744 0.56655 0.5125  1.42653
Chronic stress genes
AHSP ND 14 12.9605 0.89321 0 1
MDD only 5 12.3232 0.52023  0.6373 1.5554
MDD + anxiety disorder 9 12.7443 0.72712  0.2162 1.1616
AMFR ND 14 13.5744 1.68521 0 1
MDD only 5 13.9849 0.35561 0.4105  1.32926
MDD + anxiety disorder 9 14.4332 0.41345 0.8588  1.81357
CAT ND 14 14.6880 1.08626 0 1
MDD only 5 14.9740 0.60841 0.2860  1.21921
MDD + anxiety disorder 8 15.2509 0.37033 0.5629  1.4771
CDR2 ND 14 14.8752 0.65338 0 1
MDD only 5 15.5524 0.20734 0.6771  1.59898
MDD + anxiety disorder 8 15.2020 0.37955 0.3268  1.25423
CMAS ND 14 15.5308 2.43662 0 1
MDD only 5 17.3159 0.28832 1.7851  3.4459
MDD + anxiety disorder 8 16.6903 0.82848 1.1595  2.23364
DGKA ND 14 11.2385 1.41685 0 1
MDD only 5 10.3071 0.68101  0.9315 1.9072
MDD + anxiety disorder 9 11.6179 0.89919 0.3793  1.30073
EMB ND 14 12.7808 1.05224 0 1
MDD only 5 13.0919 0.25565 0.3111  1.24069
MDD + anxiety disorder 8 12.8555 0.73724 0.0747  1.05307
FECH ND 14 13.4058 1.15795 0 1
MDD only 5 13.7521 0.83616 0.3463  1.27126
MDD + anxiety disorder 9 13.8091 0.55241 0.4032  1.3224
GCLM1 ND 14 16.2397 0.91531 0 1
MDD only 5 16.7181 0.24730 0.4784  1.39315
MDD + anxiety disorder 8 16.2007 0.85000  0.0390 1.0274
GGA3 ND 14 15.3662 0.88044 0 1
MDD only 5 15.2748 0.63735  0.0914 1.0654
MDD + anxiety disorder 8 15.7604 0.84886 0.3942  1.31423
IRF3 ND 14 13.0719 0.95953 0 1
MDD only 5 13.0075 0.60782  0.0644 1.0457
MDD + anxiety disorder 9 13.5359 0.55548 0.4641  1.3795
KIAA1539 ND 14 13.4514 1.32581 0 1
MDD Only 5 12.8294 0.88024  0.6220 1.539
MDD + anxiety disorder 8 13.8681 1.03397 0.4168  1.33494
PSME1 ND 14 11.1975 0.53582 0 1
MDD only 5 11.6564 0.40741 0.4588  1.37438
MDD + anxiety disorder 8 11.3615 0.58138 0.1639  1.12032
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Groups N Mean, DCt
a s.d. DDCt
b Fold change
c
PTP4A3 ND 14 14.9475 0.94725 0 1
MDD only 5 15.7955 0.62373 0.8480  1.80018
MDD + anxiety disorder 8 15.4607 0.73612 0.5132  1.42714
SLC4A1 ND 14 13.1906 1.29940 0 1
MDD only 5 12.6948 1.26028  0.4958 1.4101
MDD + anxiety disorder 9 13.5886 0.74571 0.3979  1.31752
aDCt ¼ Cttargetgene Cthousekeepinggene;[Target]/[Housekeeping] ¼ 2
 DCt.
bDDCt ¼ DCt(MDDorMDD+ANX) DCt(ND).
cFoldchange ¼ 2
 DCt (MDD or MDD
+ ANX)  DCt (ND).
Table 3 Effect sizes for comparisons between no disorder (ND) vs major depressive disorder (MDD; all), and MDD-only vs MDD with comorbid anxiety disorder
Groups N Effect size Groups N Effect size
Genetic model genes
ATP11C ND 14  0.84 MDD only 5 0.49
MDD 13 MDD + anxiety disorder 8
CD59 ND 14  0.78 MDD only 5 0.94
MDD 14 MDD + anxiety disorder 9
FAM46A ND 14  0.00 MDD only 5  0.78
MDD 14 MDD + anxiety disorder 9
IGSF4A/CADM1 ND 14  0.59 MDD only 5 0.95
MDD 14 MDD + anxiety disorder 9
MAF ND 14  0.62 MDD only 5  0.10
MDD 14 MDD + anxiety disorder 9
MARKS ND 14  0.40 MDD only 5  0.37
MDD 14 MDD + anxiety disorder 9
NAGA ND 14  0.29 MDD only 5  0.94
MDD 14 MDD + anxiety disorder 9
RAPH1 ND 14  0.63 MDD only 5 0.25
MDD 13 MDD + anxiety disorder 8
TLR7 ND 14  0.00 MDD only 5  0.93
MDD 14 MDD + anxiety disorder 9
UBE3A ND 14  0.27 MDD only 5 0.41
MDD 13 MDD + anxiety disorder 8
ZNF291/SCAPER ND 14  0.36 MDD only 5  0.82
MDD only 14 MDD + anxiety disorder 9
Chronic stress model genes
AHSP ND 14  0.46 MDD only 5  0.59
MDD 14 MDD + anxiety disorder 9
AMFR ND 14  0.57 MDD only 5  1.06
MDD 14 MDD + anxiety disorder 9
CAT ND 14  0.54 MDD only 5  0.55
MDD 13 MDD + anxiety disorder 8
CDR2 ND 14  0.87 MDD only 5 0.99
MDD 13 MDD + anxiety disorder 8
CMAS ND 14  0.77 MDD only 5 0.85
MDD 13 MDD + anxiety disorder 8
DGKA ND 14  0.07 MDD only 5  1.47
MDD 14 MDD + anxiety disorder 9
EMB ND 14  0.19 MDD only 5 0.36
MDD 13 MDD + anxiety disorder 8
FECH ND 14  0.41 MDD only 5  0.08
MDD 14 MDD + anxiety disorder 9
GCLM ND 14  0.19 MDD only 5 0.69
MDD 13 MDD + anxiety disorder 8
GGA3 ND 14  0.25 MDD only 5  0.58
MDD 13 MDD + anxiety disorder 8
IRF3 ND 14  0.34 MDD only 5  0.86
MDD 14 MDD + anxiety disorder 9
KIAA1539 ND 14  0.01 MDD only 5  0.99
MDD 13 MDD + anxiety disorder 8
PSME1 ND 14  0.52 MDD only 5 0.52
MDD 13 MDD + anxiety disorder 8
PTP4A3 ND 14  0.77 MDD only 5 0.45
MDD 13 MDD + anxiety disorder 8
SLC4A1 ND 14  0.07 MDD only 5  0.88
MDD 14 MDD + anxiety disorder 9
Positive effect size indicates increased fold change compared with ND or MDD-only, whereas negative is the opposite.
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comorbid with anxiety. Third, 55% of the potential markers in
the MDD/ND panel are from the chronic stress model,
whereas nearly 70% of those in the MDD with or without
Anxiety Disorders panel are from the chronic stress model.
Chronic stress gene transcripts and chronic stress
in youths. Youths with depression had more exposure to
maltreatment than did those who did not have any disorder
(MeanMDD ¼ 41.1±5.9 (s.d.) vs MeanND ¼ 30.2±5.9 (s.d.),
effect size ¼ 1.74). CTQ Total score was correlated with 4 of
the 26 gene transcripts at the level of a medium effect size or
greater: CMAS, PSME1, PTP4A3 and IRF3. These markers
were all derived from the chronic stress model.
Discussion
Despite considerable efforts, there are still no valid, reliable
and feasible peripheral/blood biomarkers that can diagnose
MDD, classify MDD subtypes and measure treatment
response, even in adult-onset MDD.
23 Our research is unique
in the attempt to discover a biomarker panel for early-onset
MDD, a more severe disorder than adult onset. Our approach
is also innovative in combining theoretical and atheoretical
strategiesinanimalmodelsofdepressiontoidentifyapanelof
transcripts in the blood that did distinguish subjects with early-
onset MDD from those in the ND group. Moreover, a partly
overlapping set of transcripts differentiated youths with MDD-
onlyfromthosehavingMDDwithcomorbidAnxietyDisorders,
providing the ﬁrst panel of blood transcripts that might be
useful for detecting these endophenotypes.
Previous research to identify panels of blood biomarkers
has focused on serum factors
46,47 or on blood expression
biomarkers using the complex approach of Convergent
Functional Genomics developed by Le-Niculescu et al.
22
The strategy recently being used to identify serum-based
markers is to select them from biochemical domains
previously associated with MDD.
47 This approach has the
advantage of focusing on the biologically functional protein
end points. The Convergent Functional Genomics approach
combined brain and blood expression data from a pharmaco-
genomic animal model with human blood and post-mortem
expression data and human genetic linkage/association data.
This elegant assemblage of multiple levels of information has
the advantage that the markers thus selected could yield
information about genetic vulnerability and related transcrip-
tomic changes.
Our approach is not a duplication of these efforts described
above, but rather one that is based on the atheoretical, or
unbiased, exploratory exploitation of two theoretical animal
models of depression. These models comprised the genetic
and the environmental (chronic stress) components of MDD
etiology, and thereby these candidate biomarkers for MDD
highlight genetic vulnerability factors and their transcriptomic
consequences, in addition to biological costs of a repeated
stressor. The strengths of our approach include the unique-
ness of the genetic animal model we employed, and the
selection process of candidate markers. Namely, transcripts
were selected as candidates when they showed signiﬁcant
same-directional differences in any of the brain regions
examined and in the blood of the genetically ‘depressed’
WMI compared with their genetically very close control, the
WLI. This allowed us to verify that the candidate transcripts
were relevant to brain functions and, therefore, some of these
transcriptscanberegardedasprospectivenoveldrugtargets.
Anotherstrengthisthatourchronicstressbloodmarkerswere
compiled from a study of four genetically diverse strains,
thereby providing a rather narrow, but powerfully informative,
set of transcripts. These transcripts represent generalizable
responsiveness to stress and signify the notion that stress
marks all organisms, regardless of their vulnerability or
resilience.
The ﬁrst biomarker panel we deﬁne consists of 11
transcripts that differentiated youths with MDD from those
without any disorder. These candidate markers are derived
almost equally from the genetic and chronic stress models of
depression. The genes expressing these transcripts belong to
three broad functional categories: those involved in transcrip-
tion, neurodevelopment and neurodegeneration. Genes with
transcriptional regulatory functions include MAF, which
encodes a DNA-binding, leucine zipper-containing transcrip-
tion factor, and the cytoplasmic cerebellar degeneration-
related protein 2 antigen (CDR2), which harbors a helix-
leucine zipper motif and interacts speciﬁcally with c-Myc.
48
Genes that regulate, modify or interfere with neurodevelop-
ment include RAPH1 (Ras association and pleckstrin homol-
ogy domains 1, also known as LPD), which is intimately
involved in proper neuronal migration.
49 Tyrosine phospha-
tase PTP4A3, also called PRL-3, has oncogenic activity, but
has also been reported to promote cell migration.
50 CMAS
encodes an enzyme, cytidine monophosphate N-acetylneur-
aminic acid synthetase (also known as CMP-Neu5Ac synthe-
tase), which regulates brain sialylation levels and, therefore,
very likely affects brain development.
51 Cell adhesion
molecule 1 (CADM1), also known as immunoglobulin super-
family, member 4 (IGSF4), is a synaptic adhesive molecule
involved in neural cell adhesion processes and synaptogen-
esis.
52 CADM1 is thought to contribute to depressive-like
behavior in a recent mouse genetic study,
53 and has also
been linked with social impairments and anxiety-like beha-
vior.
54,55
A group of candidate biomarkers have known functions in
processes that mediate neuronal damage. PSME1 (protea-
some activator subunit 1, also called PA28a) activates the
proteosomal hydrolysis of intracellular proteins. Inadequate
glucose supplycauses damage of neuronal cells, and PSME1
is highly responsive to hypoglycemic environment in neu-
rons.
56CD59,alsocalledMIRL orprotectin,encodesasingle-
chain, glycosylphosphatidylinositol-anchored cell surface
protein structurally homologous to snake venom neuro-
toxins.
57 The protein has complement-inhibitory properties,
but its capability to mediate complement-mediated damage to
neurons is also recognized.
58–61 The CAT gene encodes
catalase, a key antioxidant enzyme that serves as a defense
against oxidative stress. Chronic unpredictable stress de-
creases CAT expression in the mouse cerebral cortex and
hippocampus;
62 these effects may be mirrored by the
decreased expression of this gene in the blood of both the
chronic stress model and subjects with MDD. The expression
of AMFR (autocrine motility factor receptor), otherwise known
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brane-anchoredubiquitinligase,isincreasedbyaccumulation
of neurodegenerative disease proteins, such as mutant
huntingtin,
63 SOD1 and ataxin-3.
64 This increase in AMFR
expression may represent a protective response to enhance
the removal of these disease proteins, and suggests that a
decrease of AMFR/GP78 expression, as we found in MDD,
might make the organism more vulnerable to these diseases.
The second panel consists of 18 transcripts that distin-
guished youths who had MDD with comorbid anxiety
disorders from those with MDD alone. Only six gene
transcripts were in both panels, and thus the majority of these
markers are unique to this diagnostic category. Furthermore,
the panel differentiating MDD youths with and without
comorbid anxiety disorders had a substantially higher number
of genes derived from the chronic stress model than from the
genetic model. These latter observations support the long-
standing clinical impression that MDD with comorbid anxiety
disorders is a unique phenotype. Moreover, it is possible that
there are different etiologic factors involved in this endophe-
notype, for example, exposure to chronic stress particularly at
the highly stressful period of adolescence. Most of these
transcripts have no known function relevant to MDD or brain,
includingthreeofthefour‘geneticdepressionmodel’markers:
FAM46A (family with sequence similarity 46, member A),
NAGA (N-acetylgalactosaminidase) and ZNF291/SCAPER
(S-phase cyclin A-associated protein in the ER). Among the
‘chronic stress model’ markers, AHSP (a hemoglobin stabiliz-
ing protein), DGKA (diacylglycerol kinase, a), SLC4A1 (solute
carrier family 4, anion exchanger, member 1) and KIAA1539
have either no brain-related functions to date or no known
function.
Genes whose transcripts differentiated MDD with and
without comorbid anxiety and which have known functions
relevant to MDD or stress encode proteins involved in
immunoregulation or neurodegeneration. IRF3 (interferon
regulatory factor 3), identiﬁed from the chronic stress animal
model, has been established previously as a chronic
psychological stress-responsive gene in human peripheral
blood cells.
65 TLR7, an intracellular Toll-like receptor, is an
innate immunity receptor that activates inﬂammation and
adaptiveimmunity. TLR7,or its agonists, induce inﬂammatory
responses in the periphery and in the brain,
66 and greater
expression of TLR7 are associated with poor functional
outcome in ischemic stroke patients.
67 Polymorphism in
GCLM (glutamate cysteine ligase modulatory subunit), the
ﬁrst rate-limiting enzyme of glutathione synthesis, has been
associated with depression and schizophrenia, although this
association has not been conﬁrmed.
68 Nevertheless, glu-
tathione deﬁcits have been observed in several neurodegen-
erative and psychiatric disorders including Alzheimer’s,
Parkinson’s or Huntington’s diseases
69 as well as in schizo-
phrenia. GGA3 (golgi-associated, gamma adaptin ear con-
taining ARF binding protein 3) is involved in the pathogenesis
of Alzheimer’s disease.
70 It is interesting to note that subjects
with lower levels of GGA3 may be at risk for developing
Alzheimer’s disease,
70 and that MDD is thought to be a
triggering or precipitating factor in Alzheimer’s disease.
Several of the blood candidate markers whose expression
differed between MDD and controls or between MDD
subtypes are involved in different neurodegenerative pro-
cesses, suggesting that MDD, and perhaps other psychiatric
illnesses, can lead to neurodegeneration. These markers,
therefore, could present a generic ‘neurodegenerative ﬁnger-
print’ in the brain and blood. Alternatively, as Alzheimer’s,
Parkinson’sand otherneurodegenerativeillnessesare known
to show symptoms of depression before their regular presen-
tation, depression might be a precipitating factor in these
illnesses indicated by the presence of these biomarkers.
When we explored associations between CTQ Total scores
and transcript levels, we found that the transcripts with
potential clinical signiﬁcance were all derived from the chronic
stress animal model. These four transcripts, CMAS, IRF3,
PSME1 and PTP4A3, share no close connections in their
functions, but their altered expressions are likely to represent
long-term consequences of maltreatment, as these youths
may have experienced maltreatment for as long ago as
8–10 years before the time of data collection.
The current study’s limitations lie in its relatively small
samples sizes and the limited number of target transcripts we
were able to pursue. Additionally, we recognize that the
animal models only mirror some aspects of early-onset MDD
and, therefore, the markers derived from them cannot be all
inclusive. Nonetheless, the purpose of this type of study in
biomarker research is to determine if there are sufﬁcient data
to proceed to a full-size study of the candidate transcripts in
a large representative sample of young people with and
without MDD.
In summary, we have taken a novel approach to identifying
potential peripheral biomarkers for early-onset MDD. The
main goal of this pilot study was to determine if blood
transcripts from both a genetic and a chronic stress animal
modelofdepressioncouldleadtocandidatebloodbiomarkers
for early-onset MDD in human subjects. The pilot data
presented here suggest that our approach leads to a clinically
valid diagnostic panel of blood transcripts that can differenti-
ate early-onset MDD from controls and MDD with from MDD
without anxiety. The next step is to test our ﬁndings in a large
sample of youths with MDD, comparing them with youths
without any psychiatric disorder and youths diagnosed with
other psychiatric disorders. Eventually, the effect of treatment
on validated biomarkers panels can be established, allowing
for further individualization of MDD treatment strategies.
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